Drug Profile
PMA 411R
Alternative Names: PMA-411RLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Pharmedartis
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammation; Leukaemia; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Atopic dermatitis in Germany (unspecified route), prior to September 2023
- 06 Sep 2023 Discontinued - Preclinical for Inflammation in Germany (unspecified route), prior to September 2023
- 06 Sep 2023 Discontinued - Preclinical for Leukaemia in Germany (unspecified route), prior to September 2023